KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Intangibles (2016 - 2026)

Supernus Pharmaceuticals has reported Intangibles over the past 15 years, most recently at $569.5 million for Q4 2025.

  • Quarterly Intangibles rose 9.11% to $569.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $569.5 million through Dec 2025, up 9.11% year-over-year, with the annual reading at $569.5 million for FY2025, 9.11% up from the prior year.
  • Intangibles was $569.5 million for Q4 2025 at Supernus Pharmaceuticals, down from $623.5 million in the prior quarter.
  • Over five years, Intangibles peaked at $784.7 million in Q4 2021 and troughed at $346.6 million in Q3 2021.
  • The 5-year median for Intangibles is $589.8 million (2023), against an average of $587.0 million.
  • Year-over-year, Intangibles soared 1421.42% in 2021 and then dropped 15.75% in 2024.
  • A 5-year view of Intangibles shows it stood at $784.7 million in 2021, then decreased by 10.48% to $702.5 million in 2022, then decreased by 14.6% to $599.9 million in 2023, then decreased by 13.0% to $521.9 million in 2024, then grew by 9.11% to $569.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Intangibles are $569.5 million (Q4 2025), $623.5 million (Q3 2025), and $481.3 million (Q2 2025).